NCT00842595View on ClinicalTrials.gov

Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive Lymphomas

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

November 30, 2009

Study Completion Date

May 31, 2010

Conditions
Diffuse Large B-Cell Lymphoma
Interventions
DRUG

rituximab

6 courses every 28 days

DRUG

vinorelbine

6 courses every 28 days

DRUG

ifosfamide

6 courses every 28 days

DRUG

Mitoxantrone

6 courses every 28 days

DRUG

Prednisone

6 courses every 28 days

Trial Locations (1)

75014

Hôpital COCHIN, Paris

All Listed Sponsors
lead

French Innovative Leukemia Organisation

OTHER

NCT00842595 - Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive Lymphomas | Biotech Hunter | Biotech Hunter